Where does MDMA-assisted therapy go from here?
Psychedelic treatments face a challenge from the FDA


The U.S. Food and Drug Administration has delivered a "critical blow" against efforts to bring psychedelics into the mainstream, said Vox. The agency rejected an application from drugmaker Lykos Therapeutics to use the drug MDMA as a treatment — combined with talk therapy — for post-traumatic stress. The rejection "does not fully quash" the psychedelic movement, but "it will delay it."
The dismissal came after studies used to support the MDMA effort "missed serious side effects," The Wall Street Journal said, and had problems with bias. The biggest problem? Some subjects told researchers "their thoughts of suicide worsened" amidst the testing, raising concerns the Journal said were not fully captured in the trial reports. "The data is reliable," said Lykos chief executive Amy Emerson.
Veterans groups have pushed for approval of psychedelics to treat trauma issues, and their cause has bipartisan support in Congress. For now, at least, that is not enough. "It's clear that the path to creating access to safe, psychedelic-assisted therapy is not going to run through Washington, D.C.," Healing Action Fund's Taylor West said to The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
What did the commentators say?
The FDA's decision "will likely only delay psychedelic medicine's official debut" as an approved treatment, Jonathan Lambert said in The Atlantic. But it could prompt a change in one of the most "poorly understood and hotly contested" issues in psychedelic therapy: the therapy itself. Advocates believe combining the drugs with talk therapy can "catalyze changes" neither accomplishes on its own. Sussing out the effects of therapy is difficult, though — and the FDA does not regulate therapy — which is why drug companies may be tempted simply to focus on the benefit of drugs alone. That could turn psychedelics "into just more pills to pop."
"Psychedelic drug development is a fraught process by nature," Arizona State University's Benjamin Y. Fong said in an interview with The Conversation. The drugs do put users in a "severely altered state" that can render them vulnerable, after all. Given that, some observers believe it will be "nearly impossible to avoid accusations of impropriety" as researchers make their way forward. They will venture ahead, but the latest setback shows how psychedelics face "unique obstacles on the way to FDA approval."
What next?
"It's not yet clear" how the FDA decision will affect future applications for psychedelic treatments, said Nature. Some advocates worry that future applicants will drop the therapy components of their proposed treatments in order to get government approval. That would be "contrary to the ethos of many who have been pressing for approval and acceptance of these substances," said Harvard bioethics expert Glenn Cohen.
"Is the medical system ready for any psychedelic?" asked Time. Any drug that does get approval will have to overcome an "overstretched therapeutic workforce, insurance headaches, concerns about safety and illicit use and logistical issues" to be fully implemented in a care setting. Getting MDMA in front of the FDA took "decades of advocacy." The final push will remain strenuous. Psychedelics are "novel treatments," said Dr. Jonathan Alpert, chair of the American Psychiatric Association's Council on Research, "and they inevitably raise novel questions."
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Joel Mathis is a writer with 30 years of newspaper and online journalism experience. His work also regularly appears in National Geographic and The Kansas City Star. His awards include best online commentary at the Online News Association and (twice) at the City and Regional Magazine Association.
-
A running list of RFK Jr.'s controversies
In Depth The man atop the Department of Health and Human Services has had no shortage of scandals over the years
By Brigid Kennedy
-
Film reviews: Sinners and The King of Kings
Feature Vampires lay siege to a Mississippi juke joint and an animated retelling of Jesus' life
By The Week US
-
Music reviews: Bon Iver, Valerie June, and The Waterboys
Feature "Sable, Fable," "Owls, Omens, and Oracles," "Life, Death, and Dennis Hopper"
By The Week US
-
RFK Jr.'s focus on autism draws the ire of researchers
In the Spotlight Many of Kennedy's assertions have been condemned by experts and advocates
By Theara Coleman, The Week US
-
Full-body scans: are Neko Health and the like more panic than panacea?
The Explainer Hailed as the 'future of medicine' by some, but not all experts are convinced
By The Week UK
-
Fighting against fluoride
Feature A growing number of communities are ending water fluoridation. Will public health suffer?
By The Week US
-
The strange phenomenon of beard transplants
In The Spotlight Inquiries for the procedure have tripled since 2020, according to one clinician, as prospective patients reportedly seek a more 'masculine' look
By Harriet Marsden, The Week UK
-
How to do the 75 Hard trend the soft way
The Week Recommends The 75 Soft Challenge might be more your speed if you're trying to hit a soft reset
By Theara Coleman, The Week US
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US
-
Health care is full of cognitive biases. Some think AI can help.
The Explainer Humans are fallible but technology can be, too
By Devika Rao, The Week US